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T CELL RESPONSES TO OSPA, A CANDIDATE LYME DISEASE VACCINE

W. Dee Dockery, Kathy Deponte, Nancy Marcantonio, Linda Bockenstedt.
Sections of Rheumatology and Allergy & Immunology, Department of
Internal Medicine, Yale University, School of Medicine, New Haven, CT.

ABSTRACT
The outer surface protein (Osp) A of Borrelia burgdorferi, the etiologic
agent of Lyme disease, is a major protein candidate for a recombinant Lyme
disease vaccine. We utilized the well-defined murine model of Lyme disease,
as well as patients with varying stages of disease, to study T cell responses to
OspA.

T cell hybridomas were generated from C3H/HeJ mice immunized

with recombinant OspA (rOspA) from Borrelia

burgdorferi, strain N40.

Antigenic specificity of the hybridomas was analyzed using rOspA and
truncated overlapping recombinant glutathione S-transferase (rGST)-OspA
fusion proteins.

Although thirteen T cell hybridomas initially responded

specifically to rOspA, none reacted with any of the rGST-OspA fragment
preparations. In the human experiments, we analyzed peripheral blood T cell
responses of patients with varying stages of Lyme disease to rOspA as well as
to rOspA digested with cathepsin D, a major lysosomal enzyme responsible
for degradation of endocytosed proteins for presentation by MHC Class II.
Purified T cells from three patients, two of whom had high-titer OspA
antibodies, and all of whom had active disease—both early disseminated and
late chronic disease—responded specifically to peptide fragments of the
cathepsin D digest of rOspA.

In contrast, no patients with inactive disease

demonstrated detectable T cell responses.

These results suggest that OspA-

specific T cell responses may be detectable in the peripheral blood of patients
only during periods of disease activity.
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INTRODUCTION

Lyme disease

Lyme disease is a multi-system disorder caused by infection with the
tick-borne spirochete Borrelia burgdorferiT

Since its first description as an

epidemic of childhood arthritis in Lyme, CT (from which the disease takes its
name), the illness has become more widespread (reported most recently in 48
of 50 states), and the spectrum of clinical manifestations has expanded, now
including irreversible cardiac, neurologic and rheumatic sequelae.

Although

treatable in its earliest stages, Lyme disease can be difficult to diagnose, and
later manifestations of the illness may be poorly responsive to antibiotic
therapy.2'5

The principal vector for Borrelia burgdorferi in the United States is the
hard-shelled tick of the Ixodes family.1 The life-cycle of the Ixodes tick spans
two years, during which time the tick matures through three separate stages:
larval, nymphal and adult. Ticks feed once per developmental stage, and it is
generally during its first blood meal that the larva becomes infected with

Borrelia burgdorferi by feeding on a carrier host. Thus, in regions where the
preferred host can act as a reservoir for Borrelia burgdorferi (such as white¬
footed mice and deer in the northeastern U.S.), prevalence of Borrelia

burgdorferi infection in ticks ranges from 10 to 50 percent. In contrast, in the
Pacific coastal regions, Ixodes ticks prefer to feed on lizards which do not carry
the spirochete, and hence tick infection rates are much lower (1 to 3 percent).
In the northeastern U.S., infection is most often transmitted to humans by
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infected nymphs, which typically feed during the summer months, from late
spring to early fall.

In humans, the clinical features of Lyme disease progress through
stages, reflecting localized versus systemic infection.1

Early disease begins

with the dermal introduction of Borrelia burgdorferi through the bite of an
infected tick and is localized to the site of the tick bite, where the
pathognomonic rash erythema migrans (EM) develops.
symptoms

marked

by

fever

lymphadenopathy can be seen.

and

generalized

Constitutional

malaise

as

well

as

After proliferating locally, the spirochete

disseminates via the bloodstream to other sites (primarily the heart, nervous
system, and musculoskeletal system), where disease manifestations can be
seen.

As is typical of other borrelial infections, signs and symptoms remit

spontaneously, even without specific therapy.

In some patients, however,

disease manifestations (primarily arthritis and neurologic disease) become
chronic, suggesting a role for genetic factors in the expression of disease. The
response of all stages of illness to antibiotics as well as the finding of viable
organisms in involved tissues suggest that persistent disease is due to the
presence of viable spirochetes that have evaded host defenses.

The

increasing

incidence,

considerable

morbidity,

occasional

recalcitrance to therapy, and impracticality of antibiotic prophylaxis have
made Lyme disease an important public health concern.

Recent research has

focused on elucidating the immunology of Lyme disease with the goal of
developing an effective recombinant vaccine.
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The human immune response

The immune response to Lyme disease in naturally infected human
hosts begins with a nonadaptive component mediated by neutrophils,
macrophages, and natural killer (NK) cells, followed by an adaptive
component involving T and B cells.6

The humoral immune response has

been most extensively studied, and a Borrelia burgdorferi-speciiic antibody
response is usually detectable in the serum within the first 4 to 6 weeks after
untreated infection.7*12 The earliest antibodies are directed against the 41 kD
flagellin protein of Borrelia burgdorferi as well as to higher molecular weight
heat-shock proteins.

Antibodies against the outer surface proteins (Osp) A

and B, which are diagnostic of immunologic exposure to Borrelia burgdorferi,
occur late in the course of infection, if at all.

Antibiotic therapy early in the

course of Lyme disease may prevent the development of detectable antibodies
against Borrelia burgdorferi, although untreated or partially treated patients
who have recurrent disease manifestations generally are seropositive.

In

addition, although acute and convalescent serum specimens may show
maturation of the antibody response from IgM to IgG antibodies, new IgM
responses may occur during exacerbations of disease.8 Despite the presence of
high-titer Borrelia

burgdorferi-specific antibodies, patients with chronic

disease do not seem to be able to clear their infection, and some researchers
have implicated the humoral response in the pathogenesis of Lyme
disease.13'14 Moreover, patients with early disease who are adequately treated
with antibiotics are not immune to reinfection.
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The mononuclear cell response to Lyme disease is less understood than
the humoral response.

Early studies documented changes in number and

responsiveness of various cell types in infected patients, including decreases
in natural killer cell activity and increases in T suppressor cell activity in the
early stages, but did not determine whether these changes were specific to
spirochetal antigens.15'16 More recent studies have demonstrated that at least
some of these changes are Borrelia

burgdorferi-specific.17' 18

Specific

responsiveness of human peripheral blood mononuclear cells to whole

Borrelia

burgdorferi lysate has been shown, with significantly higher

responses in synovial or CSF mononuclear cells when
symptoms referrable to these systems.

patients

had

Most of these mononuclear cell

responses appear to involve primarily T cells.19 These Borrelia burgdorferispecific responses have been documented in patients even in the absence of
seropositivity.20

While some have suggested that cellular responsiveness

should therefore be considered in the diagnosis of Lyme disease, others have
shown that healthy controls may exhibit similar responses.21

Relatively little is known about antigen-specific cellular immune
responses in human Lyme disease.

It is likely that T helper cells capable of

providing B cell help for antibody isotype switching exist and are an
important component of protective immunity against Borrelia burgdorferi.
CD4+ T cells have been isolated from the peripheral blood and diseased
tissues of patients with chronic Lyme disease that react with native and
recombinant forms of flagellin, heat shock protein 60, and OspA, and with
recombinant OspA peptide fragments.13' 19' 22-24 However, judging by their
lymphokine secretion profiles, these T cells appear not to be responsible for
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providing B cell help, but rather to belong to the CD4+ subset which mediates
delayed type hypersensivity.

CD8+ cells have been isolated from Lyme

disease patients, but none has demonstrated specificity for borrelial
antigens.19
The diversity of T cell populations which may respond to borrelial
antigens underscores the need to differentiate between epitopes which are
protective and those which might be pathogenic. To this end, a recent study
correlated peripheral blood mononuclear cell (PBMC) antigen specificities
with Lyme disease stage and serology in a number of patients and controls.19
PBMC responsiveness did not correlate well with serologic status, again
suggesting that non-antibody promoting T cells play a role in Lyme disease.
In addition, patients with both early and late disease showed heightened
cellular responsiveness to whole Borrelia burgdorferi and to recombinant
OspA compared to controls, but only patients with early disease demonstrated
increased T cell responsiveness to flagellin compared to controls. The study
did not investigate the stimulatory effect of OspA or flagellin fragments and
did not subtype the peripheral blood lymphocytes which were used in the
assay. Thus, to date, a detailed study which investigates epitope specificities of
T cell subtypes and correlates these with Lyme disease stage has not been
reported in the literature.
The animal model
The development of a model for Lyme disease in immunocompetent
mice has permitted more detailed analysis of the normal host response to
infection with Borrelia burgdorferi.

All strains of mice are susceptible to
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infection, although disease severity appears to vary with age and genotype.25'
27 The C3H/HeJ mouse has a genetic background making it more susceptible
to severe disease and therefore is the strain that has been most extensively
studied.

Mice challenged intradermally with Borrelia burgdorferi have viable

spirochetes in their bloodstream as early as day 3 of infection and
subsequently develop carditis and arthritis that clinically and histologically
resembles that seen in human Lyme disease.27 Disease severity peaks around
day 14 after challenge inoculation, then subsides spontaneously despite
persistent infection.

As in human Lyme disease, recurrent bouts of disease

activity can be seen.

Natural

immunity

Mice develop antibodies to a number of Borrelia burgdorferi proteins
after challenge inoculation, including the 41 kD flagellin, OspA, and OspB
proteins, although the time course of their appearance is dependent upon the
number of spirochetes inoculated.

Thus, mice inoculated intradermally with

104 spirochetes develop OspA and OspB antibodies within the first two weeks
of infection, whereas with lower syringe inocula, Osp antibodies appear much
later, if at all.28

In this regard, the murine humoral response appears

identical to that seen in human Lyme disease.

Murine cellular immune responses to Borrelia burgdorferi infection
are less well studied than human cellular responses.

Several strains of mice

pre-sensitized with inoculations of live Borrelia

burgdorferi have been

shown to exhibit delayed type hypersensitivity on subsequent intradermal
exposure to the spirochete, as well as in vitro T cell responsiveness to
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spirochetal antigens (the latter not seen in naive T cells).29

The strains

represented several H-2 haplotypes, paralleling the variety of HLA haplotypes
involved in human T cell responses to Borrelia burgdorferi.13

Another study

has documented that Borrelia burgdorferi and recombinant OspA and OspB
induce non-specific proliferation in naive murine splenocytes, primarily in
the B cell fraction.30

This finding differs from the finding in human

experiments that T cells predominate in the cellular response.
however, in its demonstration

It is similar,

that apparent antigen-specific cellular

responsiveness may actually be nonspecific, and it emphasizes the need for
caution in interpreting such assays.

To date, the specific epitopes and the

cellular subtypes involved in these responses remain unknown.

Protective immunity
Humoral immune responses are an important arm of host defense
against Borrelia burgdorferi infection.31' 32

Passive immunization of naive

mice with immune serum derived from mice infected with Borrelia

burgdorferi for 90 days confers protection against challenge inoculation with
108 spirochetes.33-35

Antibodies present in 90-day immune mouse serum

include those with specificities for flagellin, OspA, and OspB.36 The specific
antibodies that provide protection have been partially elucidated through
active immunization studies using Borrelia burgdorferi-specific recombinant
proteins.35' 37

It is interesting to note that although the predominant

humoral response in early Lyme disease is directed against the flagellin
protein, immunization of mice with a recombinant flagellin does not elicit
neutralizing antibodies.

However, active immunization of mice with
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recombinant OspA or passive administration of OspA antiserum fully
protects them from Borrelia burgdorferi challenge infection.

Similarly, OspB

antibodies confer some protection, albeit at lower challenge inocula (103),
indicating that these two outer membrane proteins are important targets of
host defense.36

Epitope mapping studies of monoclonal antibodies derived from OspA
immunized mice demonstrate that protective OspA antibodies bind a
conformational epitope included within amino acids 133 to 273, the carboxyl
half of the 273 amino acid protein.38

Using similar methods, protective

epitopes on OspB have also been localized to the carboxy terminus.39 This
finding has important implications for vaccine development, in that much of
the variation of OspA and B sequences among Borrelia burgdorferi strains is
in the carboxyl half of the protein.40' 41

Indeed, passive immunization of

naive mice with OspA antisera derived from mice immunized with OspA,
strain N40, does not protect them from challenge infection with Borrelia

burgdorferi strain 25015.42

Other immunization studies have documented

protection across some, but not all, strains, raising concerns over the
feasibility of designing a universal vaccine.

Vaccine development

The ideal recombinant OspA-based Lyme disease vaccine would be
long-lived, effective for most humans, and protective against most strains of

Borrelia

burgdorferi.

As immunologic memory is driven by T cells,

incorporation of OspA peptide sequences which are shared among strains of

Borrelia

burgdorferi

and which preferentially stimulate T helper cells
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responsible for B cell help is critical to the development of a long-lived
vaccine.

These sequences should also avoid stimulating other T cell

populations (e.g., suppressor cells, inducer cells) and should be presentable by
a range of MHC Class II phenotypes.43-48

Goal of the present study

The present study was undertaken to define regions of the OspA
protein that contain T helper cell epitopes capable of promoting protective
antibody production.

A potential outcome of the study would be the

identification of T helper cell epitopes within regions of the OspA molecule
with less strain-to-strain variation. In addition, OspA-specific T cell responses
from patients with various stages and activities of Lyme disease were studied
to determine when in the course of natural infection such responses can be
detected.
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MATERIALS AND METHODS

Murine Experiments

Animals
All murine experiments utilized 6 to 8 week old C3H/HeJ mice
purchased from The Jackson Laboratory (Bar Harbour, ME).

Mice were

housed in filter cages and given food and water ad libitum.

Mice were

sacrificed by either cervical dislocation or by carbon dioxide asphyxiation.

Stimuli
Recombinant OspA

A soluble recombinant form of OspA, strain N40 (rOspA), was obtained
from Linda Bockenstedt (Department of Internal Medicine, Yale University).
This protein differs from the native OspA in that the first 17 amino acids,
which comprise the leader sequence of the membrane-bound protein, have
been replaced with a single alanine residue.

This modification permits

expression of a soluble OspA protein in Escherichia coli (E. coli) lysates.
Briefly, the polymerase chain reaction (PCR) was used to amplify OspA-N40
genomic DNA, using appropriate oligonucleotide primers with flanking
restriction sites to facilitate subcloning.

Amplified segments were subcloned

into the vector pET 9c (Novagen, Madison, WI), which utilizes transcription
and translation signals from bacteriophage T7.

E. coli strain DH5oc was

transformed with the plasmid, and protein expression was induced with
isopropyl (3-D-thiogalactoside (IPTG). The induced rOspA was purified by ion
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exchange chromatography as previously described.49

The resultant protein

was greater than 90 percent pure as determined by SDS-PAGE and reacted on
immunoblots with anti-N40 antisera.

Immunization of mice with the rOspA

conferred protection against challenge infection (data not shown).

Glutathione S-transferase

The plasmid pGEX-2T (Pharmacia Fine Chemicals, Piscataway, NJ)
contains the gene encoding glutathione S-transferase (GST) under the control
of the tac promotor.

E. coli DH5a were transformed with pGEX-2T, and

protein expression was induced with IPTG. Induced recombinant GST (rGST)
was purified to homogeneity by passing E. coli lysate supernatants over
glutathione sepharose 4B beads (Pharmacia) according to the manufacturer's
protocol.

rGST-OspA fusion proteins

OspA-N40 fragments, recombinantly expressed as fusion partners with
GST as previously described,38 were obtained from Erol Fikrig (Department of
Internal Medicine, Yale University).

Briefly, OspA gene fragments were

amplified by PCR using oligonucleotide primers containing restriction
enzyme recognition sites to facilitate subcloning.

Amplified fragments were

digested with the appropriate restriction enzymes, purified by agarose gel
electrophoresis, and then subcloned into pGEX-2T in frame with the GST
gene.

Following transformation of E. coli with the plasmid, protein

expression was induced with IPTG.

Induced rGST-OspA proteins contained

in the cell lysate supernatant were purified using glutathione sepharose 4B
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columns (Pharmacia).

Anti-OspA antisera bound to each rGST-OspA

fragment on immunoblots.38 Recombinant GST-OspA fragments used in the
present study were as follows (Figure 1): fragment 1 (OspA amino acids 1-76),
fragment 2 (OspA amino acids 66-143), fragment 3.4 (OspA amino acids 133273), fragment 550 (OspA amino acids 183-273), fragment 650 (OspA amino
acids 216-273), and fragment 9 (OspA amino acids 243-273).

Preparation of murine antigen presenting cells
Spleens were harvested from normal or rOspA-immunized mice and
disrupted using glass slides into single cell suspensions in Dulbecco's
Modified

Essential

Medium

(DMEM)

supplemented

with

10%

heat-

inactivated fetal calf serum and 1% penicillin/streptomycin/L-glutamine
(complete DMEM-10).

Splenocytes were washed, then incubated for 5

minutes at room temperature with 5 ml red blood cell lysing buffer (Sigma
Chemical, St. Louis, MO).

After washing twice in complete DMEM-10, cells

were resuspended at a concentration of 2 x 106 cells/ml and irradiated (2500
rads) using a cesium source.

Generation of murine T cell hybridomas
Murine T cell hybridomas were obtained from Linda Bockenstedt
(Department of Internal Medicine, Yale University).

Mice were immunized

via footpad and base of tail with 50 |ig rOspA in complete Freund's adjuvant.
Ten days after immunization, mice were sacrificed, and regional lymph nodes
were removed and dissected into single cell suspensions. 5 x 106 lymph node
cells were cultured with 50 pg/ml rOspA for 3 days in complete DMEM-10,
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then fused with an equal number of BW5147 lymphoma cells using 50%
polyethylene glycol as described.50' 51 Successful fusions were selected using
hypoxanthine-aminopterin-thymidine

(HAT)

medium supplement, and

individual hybridomas were screened for rOspA specificity by testing their
ability to produce lymphokines in response to this antigen.

A total of 19

rOspA-specific hybridomas were obtained from two separate immunization
procedures and used in the present studies.

Hybridomas were maintained in complete DMEM-10 supplemented
with hypoxanthine-thymidine (HT) plating medium.

At the time of assay,

the desired number of cells were aliquoted into 15 cc conical tubes, washed
twice, and resuspended at a concentration of 106 cells/ml in complete DMEM-

10.
Stimulation tests
Interleukin quantification assay

The murine T cell hybridoma stimulation experiments utilized a
previously described assay using the IL-2/IL-4-dependent CTLL-2 murine T
cell line.52' 53 This assay indicates the presence of IL-2 or IL-4 in a test solution
by determining the viability of CTLL-2 cells (as determined by 3H-thymidine
incorporation) after 48-hour incubation in the solution relative to control IL2.

The CTLL-2 line is dependent upon IL-2 or IL-4 for cell growth and

therefore can be used as an indicator for the presence of these lymphokines in
hybridoma supernatants.
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The CTLL-2 cell line was obtained from Kathy Deponte (Department of
Internal Medicine, Yale University).
medium

(DMEM

supplemented

Cells were maintained in IL-2 assay
with

10%

fetal

calf

serum,

1%

penicillin/streptomycin, 1% L-glutamine, and 5 x 10'5 M (3-mercaptoethanol),
with human recombinant IL-2 (rIL-2, Gibco BRL, Grand Island, NY) added
weekly to a final concentration of 1 U/ml to sustain growth.

Cells were

collected for interleukin quantification one day prior to their scheduled IL-2
feedings.

CTLL-2 cells were washed 3

times in IL-2-free medium,

then

resuspended at 105 cells/ml in IL-2 assay medium. 5 x 103 CTLL-2 cells were
added to the wells of flat-bottom, 96 well microtiter dishes.

In a control

experiment, these cells were incubated with 50 pi aliquots of rIL-2 at varying
concentrations, in a total volume of 100 pi for 48 hours at 37° C.

In

subsequent experiments, the cells were incubated with 50 pi of either IL-2
assay medium, hybridoma supernatant (see below), or 1.3 U/ml rIL-2.
Initially, 1 pCi 3H thymidine (Tdr, 80 Ci/mmol, DuPont NEN, Boston, MA)
was added to each well during the last 18 hours of culture, after which cells
were harvested and counted using a Beckman beta-scintillation counter.
Later experiments (see figure legends) added 3H-thymidine only during the
final four hours of culture.

Screening of hvbridomas for rOspA and rGST-OspA reactivity

105 hybridoma cells were cultured in triplicate in 200 pi final volume
with 106 splenocytes and either medium alone or the following experimental
antigens:

rOspA (50 pg/ml), rGST (50 pg/ml), and rGST-OspA fusion
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fragments (10 pg/ml).

Recombinant GST and rOspA were used at 10 pg/ml

final concentration when they served as controls for the rGST-OspA fusion
fragment stimulation tests.

Cultures were incubated for 48 hours at 37° C,

after which time supernatants (100 X from each well) were collected,
combined within triplicates, and assayed for the presence of interleukin as
described above.

Human Experiments

Patients
The patients in this study attended the Yale University Lyme Disease
Clinic or came from private physician offices in the area (Table 1).

All

patients satisfied the Center for Disease Control (CDC) criteria for Lyme
disease.

Patient D.D. was a healthy volunteer without prior documentation

of Lyme disease or tick bite, and with negative serologies.

Patient N.R. had a history of acute disseminated Lyme disease
manifested by erythema migrans and seronegative lymphocytic meningitis;
these had resolved with antibiotic therapy, and N.R. had been symptom-free
for several months at the time of testing.

Patient A.G. had a history of acute disseminated disease, initially
presenting with third-degree atrioventricular block.

This condition required

hospitalization and resolved with antibiotics; A.G. was tested shortly before
discharge from the hospital, at which time elevated IgG responses against
several Borrelia burgdorferi proteins, including OspA, were present.
responses were not detected.

IgM
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Patient J.B. also had acute disseminated Lyme disease presenting with
third-degree atrioventricular block.

This condition resolved over two days

with antibiotics, and J.B. was tested shortly before hospital discharge. Unlike
patient A.G., J.B. had positive Lyme titers of both IgM and IgG; neither of
these responses, however, was against OspA or OspB.

Patient S.A. had a two-year history of Lyme arthritis of the knee which
had resolved following antibiotic therapy and arthroscopic synovectomy.
Although IgM antibodies were never detected, S.A. exhibited a high IgG
response against several Borrelia burgdorferi proteins, including OspA and
OspB, during active disease.

This response had fallen to 1:1600 (with no

detectable anti-Osp antibodies) at the time of the current study, at which time
the disease had been inactive for one year.

Patient A.C. had chronic active Lyme disease manifested primarily by
persistent arthritis which was clinically active at the time of testing. High IgM
and IgG Lyme titers detected by ELISA during the period of most active
disease had fallen somewhat by the time of this study, although IgG responses
against a number of spirochetal antigens, including OspA, remained
detectable by Western blot.

T cell stimulation tests (see below) of patients D.D., N.R., and S.A. were
performed by Dee Dockery, while tests of A.G., J.B., and A.C. were conducted
by Kathy Deponte and Nancy Marcantonio (Department of Internal Medicine,
Yale University).

Stella Cretella or Erol Fikrig (Department of Internal

Medicine, Yale University) provided serologic data.
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Stimuli
Phytohemagluttinin

Phytohemagluttinin (PHA, Burroughs-Wellcome, Research Triangle
Park, NC) was used as a non-specific mitogen at 1 pg/ml final concentration.

Recombinant OspA

Recombinant OspA was prepared as described above.

OspA cathepsin digests

Separate fractions of peptide fragments from cathepsin D digestion of
rOspA

were obtained from Kathy

Deponte and Nancy

(Department of Internal Medicine, Yale University).

Marcantonio

Briefly, 2 mg rOspA (in

500 pi as a stock solution) was resuspended in an equal volume of 160 mM
sodium acetate buffer, pH 4.0. 100 jil of cathepsin D stock (Sigma, 5 U/ml) was
added, and the solution was incubated in a 37° C water bath for 7 hours.
Another 100 pi of cathepsin D was added to the sample, and it was incubated
in a 37° C water bath overnight.

200 pi of 2M Tris/HCl was added to the

sample to terminate the reaction.

An equal volume of acetonitrile was then

added to the sample to precipitate large residues.

After cooling to room

temperature for 4 hours, the sample was centrifuged, and the supernatant was
collected, lyophilized, and sent to the Yale Protein Chemistry Laboratory (Ken
Williams) for fractionation over an HPLC column.

An automatic peak

detector identified peptide fragments, and these were collected in fractions at a
rate of 0.5 ml/minute.
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Preparation of human antigen presenting cells
120 ml of blood was obtained from each human volunteer from an
antecubital vein using aseptic technique.

Peripheral blood lymphocytes

(PBLs) were separated by Ficoll-hypaque centrifugation and washed twice in
RPMI 1640 medium (RPMI).

The cell pellet was resuspended in 5 ml red

blood cell lysing buffer (Sigma) and incubated at room temperature for 5
minutes. The resultant purified PBLs were washed twice and resuspended in
RPMI supplemented with 10% FCS, 1% penicillin/streptomycin and 1%
glutamine

(complete RPMI-10).

(Some experiments

utilized

RPMI

supplemented with 8% autologous serum in place of 10% fetal calf serum; see
figure legends.) Half of the PBL's were irradiated (2500 rads, cesium source)
for use as antigen presenting cells, and T cells were purified from the
remainder.
Preparation of human T cells
PBLs were depleted of adherent cells by plastic adherence for 1 hour at
37°C. T cells were purified from the nonadherent cell population by passing
over a nylon wool column as described.54' 55 Typical yields of purified T cells
from 120 ml of whole blood were 2 x 107 cells.
Stimulation tests
40 pi aliquots were collected from each fraction of cathepsin D-digested
rOspA, and aliquots from sequential fractions were often pooled.

The

resulting solutions were dried in a speed vac and resuspended in 320 pi assay
medium.
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5 x 105 T cells were cultured in triplicate in 200 pi final volume with 106
APCs and 100 pi of cathepsin D-digested rOspA fractions.

Control stimuli

included phytohemagluttinin (PHA, 1 pg/ml), rOspA (50 pg/ml), whole
cathepsin digest of rOspA, and assay medium alone.

After two days in a

humidified CO2 incubator at 37° C, 1 pCi 3H-thymidine was added to each
well for four hours.

Cells were then harvested from each well using a

Skatron harvester, and cellular proliferation measured by quantitating
incorporation of 3H-thymidine into cells with a Beckman beta-scintillation
counter.
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RESULTS

Murine Experiments

Validity of interleukin quantification assay
The CTLL-2 assay accurately quantified interleukin levels in control
solutions (Figure 2). Cells in the system failed to proliferate in medium alone
and in medium with rOspA (negative controls), but exhibited a characteristic
proliferative response when exposed to various concentrations of rIL-2:
positive dose-responsiveness at low to medium interleukin concentrations
and inhibition at high concentrations.

Initial screening of murine T cell hybridomas
In order to determine regions of the OspA protein that contained
peptides reactive with T cells from C3H/HeJ mice, T cell hybridomas were
generated from mice immunized with rOspA. Of 13 successful fusions tested
from one immunization experiment, all showed reactivity to rOspA, whereas
a control T cell hybridoma specific for the acetyl choline receptor and another
specific for ovalbumin did not (Figure 3).

Supernatants from unstimulated

hybridomas did not support the growth of CTLL-2 cells, confirming that these
hybridomas did not spontaneously secrete interleukins nor did they react
with antigenic components present in fetal calf serum.

The rOspA-specific

hybridomas were subsequently frozen in liquid nitrogen for several months
until rGST-OspA proteins were available to test their specificities.
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When retrieved from storage in liquid nitrogen, the rOspA-specific T
cell hybridomas were again screened using the CTLL-2 assay for reactivity
with rOspA.

Of 12 unstimulated hybridomas tested (data not shown),

supernatants from three (#1, 3, and 9) stimulated CTLL-2 cell growth,
suggesting

that

they

responded

spontaneously secreted interleukins.

to

antigens

in

fetal

calf serum

or

Analysis of supernatants from multiple

hybridoma culture preparations stimulated with either a control antigen
(rGST) or with rOspA indicated that only one hybridoma (#12) consistently
responded to rOspA (Figures 4, 5, and 6). Because of the low retrieval rate of
rOspA-specific T cell hybridomas from storage, a second panel of T cell
hybridomas was generated from mice immunized with rOspA.
successful fusions, none showed specificity for rOspA (Figure 7).

Of five

Thus, only

hybridoma #12 was selected to undergo stimulation with rGST-OspA
fragments.

The overall degree of 3H-thymidine incorporation differed significantly
among these screening assays. In the assays pictured in Figures 2, 4, and 5, 3Hthymidine was added a day before cell harvesting. In the remaining assays, all
with lower counts, 3H-thymidine was added only four hours before
harvesting (see figure legends).

Stimulation of murine T cell hybridoma #12 with rGST-OspA fragments
Hybridoma #12 was stimulated for 48 hours with either rGST, rOspA
or the rGST-OspA truncated fragments, after which supernatants were tested
for the presence of IL-2 and IL-4 (Figure 8).

Although previously reactive to

rOspA, hybridoma #12 failed to react with either rOspA or any of the rGST-

s
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OspA fragments when compared to negative controls. Indeed, 3H-thymidine
incorporation was low in all preparations.

Repeating the experiment using

recently passaged hybridoma cells yielded similar results (data not shown).

Human Experiments

Stimulation of human peripheral T lymphocytes with OspA fragments
The second phase of this study was to evaluate responses of T cells
from patients with varying stages and activity of Lyme disease to rOspA and
to rOspA peptide fragments.

Recombinant OspA peptide fragments were

generated by digesting rOspA with cathepsin D, a major lysosomal enzyme
involved in processing endocytosed antigen for presentation by MHC Class II
molecules.56

The peptide fragments generated were too numerous to test

individually and therefore were grouped according to time period collected
(duration of collection time ~ amount of peptide).

Positive responses were

those which exceeded ten thousand counts per minute and which were more
than three times greater than responses to medium alone.

Nylon wool purified T cells (NWTs) from one control subject without
documented tick bite or Lyme disease responded to the whole digest but to
none of the fractions (Figure 9); in addition, background responsiveness was
high compared to other patients. The response to whole digest was surprising
and may have been due to non-specific mitogens in the preparation or to
subclinical

exposure

to

Borrelia

burgdorferi in the laboratory.

T cell

responsiveness to Borrelia burgdorferi antigens in control populations has
been seen in other studies as well.21
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NWTs were isolated from patients with acute disseminated Lyme
disease during and shortly after disease activity was apparent clinically (N.R.,
A.G., and J.B.). Two patients with chronic disseminated Lyme disease, one of
whom had significant persistent disease (A.C.) and the other who had not had
disease activity for over a year (S.A.) were also studied.
and antibody reactivities are shown in Table 1.

The patient profiles

NWTs from patient N.R.,

who was tested several months after resolution of Lyme meningitis, failed to
respond to rOspA or to any OspA fragments (Figure 10).

Two patients

presented with third degree heart block and were tested during their illness or
within a month thereafter. Patient A.G. had serum antibodies to OspA at the
time of the study; NWTs showed partial reactivity with rOspA and with
fraction 48-54 of the digest, and full reactivity with the rOspA digest; the
response to PHA in this patient was low compared to the other patients
whose response to PPLA was assayed (Figure 11). Patient J.B. had no detectable
serum antibodies against OspA, but NWTs from this patient also showed
reactivity with several rOspA peptide fragments (Figure 12).

J.B.'s NWT

responsiveness was unusual, however, in that T cells responded more to
medium than to whole OspA digest.

The responses of NWTs from patients with chronic disseminated
Lyme disease, both of whom had serum antibodies to OspA, were correlated
with disease activity in a manner similar to that of patients with early acute
disseminated disease.

NWTs from patient S.A., who had chronic inactive

Lyme disease and a history of OspA seropositivity, but negative OspA
serology at the time of this study, responded to the rOspA digest in a pattern
indistinguishable from that of patient N.R. (Figure 13).

However, NWTs
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from patient A.C., with chronic active Lyme disease and moderate anti-OspA
titers, clearly responded to one cluster of fractions (16-21) of the rOspA digest
(Figure 14).

Also, like patient J.B., A.C.'s NWT response to intact OspA was

little different from the response to medium alone.
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DISCUSSION

At the present level of understanding, Lyme disease remains both a
puzzling

and

debilitating

illness.

Improved

clinical

management-

prevention, diagnosis, therapy, prognosis—requires a firmer understanding of
its pathogenesis and of the host immune response to infection.

A wealth of

literature has been reported on the B cell responses of mice and humans
infected with Borrelia burgdorferi, but relatively little is known about cellular
responses.

Recently a recombinant vaccine has been developed using the

full-length OspA protein from Borrelia burgdorferi. The efficacy and safety of
this vaccine is as yet unknown. The studies reported herein were undertaken
with two goals in mind:

the first, to determine regions of the OspA protein

that stimulate T helper cell responses capable of promoting specific antibody
production; and the second, to determine at what point during natural
infection T cell responses to OspA can be detected.

The murine experiments

in the present study focused on the former context, while the human
experiments focused on the latter.

Murine experiments

The murine experiments in the present study were designed to
determine which regions of the OspA protein contain epitopes recognized by
T cell receptors present in the repertoire of the C3H/HeJ mouse.

During the

course of natural Borrelia burgdorferi infection, it has not been possible to
demonstrate convincingly that OspA-specific T cells are present in mice.30
We had hoped that immunization of mice with rOspA using adjuvant would
allow for the isolation of T cells reactive with rOspA.

Although the initial
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screen of T cell hybridomas suggested that they were OspA-specific,
subsequent analysis failed to support this conclusion.

It is possible that

cryostorage of the hybridomas, which were not clonal, permitted the growth
of

contaminating

subculturing.

nonspecific

hybridomas

or

other

cell

types

upon

The single hybridoma that appeared specific for rOspA

(hybridoma #12) after cryostorage did not retain this phenotype after
passaging in culture over time.

Although not tested by immunofluorescence

staining, the most likely reason for loss of specificity is the loss of T cell
receptor expression on the cell surface, a phenomenon not infrequently
encountered in long-term culture of hybridomas.

A second panel of T cell

hybridomas generated from rOspA-immunized mice showed no OspA
specificity, and given the time limitations of the study, generation of
additional panels was not attempted.

Human experiments

The human experiments in the present study were designed to identify
segments of the OspA protein which stimulate the T cells of patients with
Lyme disease and to identify correlations between cellular responsiveness and
clinical parameters such as disease stage, disease activity, and serologic status.

Although OspA constitutes the majority of the outer surface protein of

Borrelia burgdorferi, OspA-specific antibodies are usually undetectable in
early disease.

The reasons for this are unknown.

One may look to the

spirochete itself and speculate that OspA expression is down-regulated during
early infection and subsequently expressed for particular reasons (such as
invasion of endothelial cells) during the spirochete life span, or that OspA
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eludes detection by mutation or genetic recombination.

Such spirochete-

oriented models would predict low levels of T cell priming in early disease
which, during the process of dissemination, increase to levels which can
provide B cell help.

OspA-specific T cell responses might increase shortly

before the appearance of anti-OspA antibodies and enter a memory cell
population as the disease activity subsided.

Alternately, host factors may explain the late seroconversion to OspA.
OspA and other borrelial antigens may stimulate cell populations which do
not contribute to, or which even inhibit, anti-OspA antibody production.
Though their cell sampling method was non-random, Peltz et al. have
documented preferential activation of Borrelia burgdorferi-specific T helper
type 1-like cells in seronegative patients with active disease and have
suggested that this CD4+ subset, unlike T helper type 2 cells which stimulate
antibody production, may actually play a pathogenic role.23

This model

would predict low or absent T helper 2 cell priming in early disease, with
varying levels of T helper 1 priming, possibly correlating with disease activity,
and increasing responsiveness of both types of CD4+ T cells later in disease.
OspA-specific

T

cell

responses

would

appear

perhaps

long

before

seroconversion and would wax and wane with disease activity.

The preliminary results of our human experiments are consistent with
both models of T cell behavior.

T cells from controls and from patients with

both early and late inactive disease (D.D., N.R., S.A.), all of whom were OspA
seronegative at the time of this study, failed to respond convincingly to OspA
in its intact or fragmented form.

(The control's response to whole digest in
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the presence of elevated background responsiveness was of questionable
significance and needs to be reassayed.)

In contrast, patients with early and

late active disease (A.G., J.B., A.C.), two of whom were OspA seropositive, did
demonstrate T cell responses against intact OspA and against certain fractions
of the cathepsin D digested protein. (An irregularity in these results involves
patient J.B.'s greater response to medium alone than to rOspA or to whole
OspA digest; patient A.C., too, showed an only marginally increased response
to OspA compared to medium.

Though these effects could result from

epitope-specific T cell suppression (see below), these experiments also need to
be repeated.)

In this small sample, then, T cell responsiveness to OspA correlated
reasonably well with both disease activity and OspA seropositivity.

If the

former correlation persists after studying more patients, one might suppose
that the responsive T cells are of the T helper type 1-like subset and may be
contributing to disease activity and possibly inhibiting antibody production
(model #2).

However, if T cell responsiveness to OspA ultimately correlates

better with OspA seropositivity, then one may speculate that the T helper type
2-like subset is the predominant responder and that late seroconversion
results from spirochetal factors (model #1).

This model could explain

occasional cases of T cell responsiveness in the absence of seropositivity (e.g.,
patient J.B.) as the result of lagging B cell responses to T cell help.
types, of course, could be involved simultaneously.

Both cell

And which model is

operative may differ among patients, depending possibly on their T cell
profiles or other immune system factors.

In order to clarify these possible
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correlations, we plan to characterize T cell subsets explicitly in future human
experiments using monoclonal antibody to cell surface markers.

Interestingly, patient A.G. with early active disease showed decreased
responsiveness to PHA when compared to the control subject and to patients
with inactive disease.

Though one can make no conclusions without

measuring PHA responsiveness among the other patients with active disease,
this finding is generally consistent with the report of Moffat et al. which
documented increased suppressor cell activity and decreased responsiveness
to PHA in early Lyme disease.15

Studying more patients would clarify this

relationship.

When T cell stimulation was seen, responses to recombinant OspA or
whole-digest were lower than responses to the individual stimulatory
fractions in two cases (patients A.C. and J.B.).

This finding may have been

due simply to higher antigen concentrations in the fractions.
concentrations were not measured in these assays.)

(The

Alternately, this effect

may have resulted from epitope-specific T cell suppression, in which the
effects of suppressive epitopes in a system outweigh those of stimulatory
epitopes contained on other antigens in the system or even within other
regions of the same protein.48

In the current experiments, full-length OspA

and whole cathepsin digests possibly contained such a range of counterregulatory epitopes, causing a net decrease in T cell proliferation.

Certain

fractions happened to be enriched for stimulatory epitopes, leading to greater
proliferation in patients with these epitope specificities.

Identifying these

stimulatory epitopes is of course crucial for designing the maximally effective
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vaccine.

Accordingly, this lab is now seeking to isolate the individual

fragments which make up the stimulatory fractions.
Also of ongoing interest is the problem of generalizability of these in
vitro results to the in vivo setting. Although the posited role of cathepsin D
in processing antigens for presentation with major histocompability complex
(MHC) proteins was the rationale for using this enzyme in the current
experiments, recent data suggests that APCs must be present for cathepsin D
to process antigen into physiologically relevant peptides.57 Class II MHC
proteins on APCs may serve to bind epitopes prior to digestion of overlapping
ends by cathepsin D.

Digestion of antigen in their absence may yield non-

physiologic peptide fragments.

Future experiments which include APCs in

the cathepsin D digestion will clarify their role in this early phase of antigen
presentation.
Future Directions
The goals of the present study—to identify OspA epitopes which
stimulate T helper cells to promote antibody production, and to elucidate the
temporal properties of OspA-specific T cell responses during the course of
natural infection—are related.

Future research will focus on further

integrating these two perspectives, correlating the clinical, microbiologic, and
serologic features of Lyme disease with T cell subtype responses to OspA
epitopes.

For example, how does the repertoire of OspA-specific T cells

evolve during the course of infection, and is there a correlation between
epitopes recognized and disease severity? Does the activity of T cell subtypes
vary through disease, with T helper 1-like responses dominating during
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active disease, and T helper 2-like responses appearing only later with OspA
seroconversion?

Answering these questions may provide pathogenetic and

clinical insights.

Thinking in terms of pathogenesis, for example, we might

find that late OspA seroconversion and late disease exacerbations correspond
to the delayed emergence of Borrelia burgdorferi from immunoprivileged
sites, with simultaneous activation of T helper 1 and 2 subtypes.

Thinking

clinically, we might find that early T cell responses to OspA in the absence of
measurable antibody titers predict worse outcomes—i.e., those patients who go
on

to develop secondary and

"adequate" therapy.

tertiary disease manifestations

despite

And patients with certain T cell response profiles may

benefit from different treatment regimens than other patients.

Though

rooted in the search for a vaccine, these findings would have more general
value in improving the understanding and management of Lyme disease.
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FIGURE LEGENDS
Figures are attached. Legends for each figure are listed below. Positive
and negative CTLL-2 controls were performed for each assay described in
Figures 3 through 8, and they were normal, except as noted. Positive control
was rIL-2 (50 pi, 1.3 U/ml starting concentration); negative control was assay
medium. Ordinate axes were scaled equally for experiments performed under
similar conditions.

Figure 1
Recombinant OspA and GST-OspA fragments.

Numbers refer to the

amino acid residues of full-length OspA.

Table 1
Clinical and serologic characterization of human Lyme disease patients.
Serologic data are expressed as most dilute titers which resulted in a positive
ELISA for Borrelia burgdorferi antigens—i.e., larger numbers to the right of
the colon indicate higher antibody levels.

N/A = not applicable or not

available, EM = erythema migrans, Antibx = antibiotics.

Figure 2
Proliferative responses of CTLL-2 cells to various stimuli, measured as
3H-thymidine incorporation and quantified as counts per minute (cpm).
CTLL-2s were incubated with antigen overnight, then pulsed with 3Hthymidine overnight.

Stimuli included assay medium alone, rOspA (50

pg/ml), and rIL-2 (various concentrations).
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Figure 3
Proliferative responses of CTLL-2 cells to the supernatants of various
hybridoma cultures, measured as 3H-thymidine incorporation and quantified
as counts per minute (cpm).

Hybridomas (#1-#14, except #10) were cultured

for two days with the indicated antigens in the company of APCs, and the
supernatants were used to stimulate CTLL-2 cells.

CTLL-2s were incubated

with supernatants for two days, then pulsed with 3H-thymidine for four
hours.

Unrelated

hybridomas

were

included

as

negative

controls:

Hybridoma A was prepared from a mouse immunized with ovalbumin, and
hybridoma B was prepared from a mouse immunized with acetylcholine
receptor.

The APCs used in this assay were from C3H/HeJ mice previously

immunized with rOspA.

Antigens included assay medium alone, rGST (50

pg/ml), and rOspA (50 pg/ml).

Figure 4
Proliferative responses of CTLL-2 cells to the supernatants of various
hybridoma cultures, measured as 3H-thymidine incorporation and quantified
as counts per minute (cpm).

Hybridomas (#1-#14, except #5 and #6) were

cultured with the indicated antigens in the company of APCs, and the
supernatants were used to stimulate CTLL-2 cells.

CTLL-2s were incubated

with supernatants for one day, then pulsed with 3H-thymidine overnight.
The APCs used in this assay were from naive C3H/HeJ mice and were not
irradiated. Antigens included rGST (50 (ig/ml) and rOspA (50 pg/ml).

41

T Cell Responses to OspA

Figure 5
Proliferative responses of CTLL-2 cells to the supernatants of various
hybridoma cultures, measured as 3H-thymidine incorporation and quantified
as counts per minute (cpm).

Hybridomas #1 to #14 were cultured with the

indicated antigens in the company of APCs, and the supernatants were used
to stimulate CTLL-2 cells. CTLL-2s were incubated with supernatants for one
day, then pulsed with 3H-thymidine overnight. An unrelated hybridoma was
also included as a negative control:

Hybridoma A was prepared from a

mouse immunized with SmD, a common autoantigen in systemic lupus.
The APCs used in this assay were from naive C3H/HeJ mice and were
irradiated. Antigens included rGST (50 pg/ml) and rOspA (50 pg/ml).

Figure 6
Proliferative responses of CTLL-2 cells to the supernatants of various
hybridoma cultures, measured as 3H-thymidine incorporation and quantified
as counts per minute (cpm).

Hybridomas #6, #10, #12, and #14 (two

hybridomas previously positive, and two previously negative) were cultured
with the indicated antigens in the company of APCs, and the supernatants
were used to stimulate CTLL-2 cells.

CTLL-2s were incubated with

supernatants for two days, then pulsed with 3H-thymidine for four hours.

A

parallel experiment used APCs without any hybridoma (column 1) as a
negative control.

The APCs used in this assay were from naive C3H/HeJ

mice and were irradiated.

Antigens were newly made in this assay and

included assay medium alone, rGST (50 |ig/ml), and rOspA (50 pg/ml).
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The CTLL-2 assay controls failed in this experiment for unknown
reasons (data not shown). It is possible that the positive and negative control
antigens were mixed up.

Figure 7
Proliferative responses of CTLL-2 cells to the supernatants of various
hybridoma cultures, measured as 3H-thymidine incorporation and quantified
as counts per minute (cpm).

Hybridomas #15 through #19 were cultured

with the indicated antigens in the company of APCs (except as noted), and the
supernatants were used to stimulate CTLL-2 cells.

CTLL-2s were incubated

with supernatants for two days, then pulsed with 3H-thymidine for four
hours.

The APCs used in this assay were from C3H/HeJ mice previously

immunized with recombinant OspA and were irradiated.

Antigens included

assay medium alone, rGST (50 pg/ml), and rOspA (50 |ig/ml).

Figure 8
Proliferative responses of CTLL-2 cells to the supernatants of various
hybridoma #12 cultures, measured as 3H-thymidine incorporation and
quantified as counts per minute (cpm). Hybridoma #12 was cultured with the
indicated antigens in the company of APCs (except as noted), and the
supernatants were used to stimulate CTLL-2 cells.

CTLL-2s were incubated

with supernatants for two days, then pulsed with 3H-thymidine for four
hours.

The APCs used in this assay were from C3H/HeJ mice previously

immunized with recombinant OspA and were irradiated.

Antigens included
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assay medium alone, rGST (10 pg/ml), rOspA (10 pg/ml), and the indicated
rGST-OspA fragments (10 |ig/ml).
Figure 9
Proliferative responses of human nylon wool-purifed (NWP) T cells to
various stimuli, measured as 3H-thymidine incorporation and quantified as
counts per minute (cpm).

T cells from healthy control D.D. were incubated

for two days with the indicated antigens in the company of APCs, then pulsed
with 3H-thymidine for four hours.

Stimuli included assay medium alone

(supplemented with autologous serum), PHA (1 pg/ml), whole digest of
OspA by cathepsin D (concentration unknown), and various fractions (Fx) of
the digest (concentrations unknown).
Figure 10
Proliferative responses of human nylon wool-purifed (NWP) T cells to
various stimuli, measured as 3H-thymidine incorporation and quantified as
counts per minute (cpm). T cells from patient N.R. were incubated for two
days with the indicated antigens in the company of APCs, then pulsed with
3H-thymidine for four hours.

Stimuli included assay medium alone

(supplemented with autologous serum or fetal calf serum), PHA (1 pg/ml),
rOspA (50 |ig/ml), and various fractions (Fx) of the cathepsin D digest of OspA
(concentrations unknown).
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Figure 11

Proliferative responses of human nylon wool-purifed (NWP) T cells to
various stimuli, measured as 3H-thymidine incorporation and quantified as
counts per minute (cpm).

T cells from patient A.G. were incubated for two

days with the indicated antigens in the company of APCs, then pulsed with
3H-thymidine for four hours.

Stimuli included assay medium alone

(supplemented with fetal calf serum), PHA (1 pg/ml), rOspA (50 pg/ml),
whole digest of OspA by cathepsin D (concentration unknown), and various
fractions (Fx) of the digest (concentrations unknown).

Figure 12

Proliferative responses of human nylon wool-purifed (NWP) T cells to
various stimuli, measured as 3H-thymidine incorporation and quantified as
counts per minute (cpm).

T cells from patient J.B. were incubated for two

days with the indicated antigens in the company of APCs, then pulsed with
3H-thymidine for four hours.

Stimuli included assay medium alone

(supplemented with fetal calf serum), rOspA (50 (ig/ml), whole digest of OspA
by cathepsin D (concentration unknown), and various fractions (Fx) of the
digest (concentrations unknown).

Figure 13

Proliferative responses of human nylon wool-purifed (NWP) T cells to
various stimuli, measured as 3H-thymidine incorporation and quantified as
counts per minute (cpm).

T cells from patient S.A. were incubated for two

days with the indicated antigens in the company of APCs, then pulsed with
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3H-thymidine for four hours.

Stimuli included assay medium alone

(supplemented with autologous serum), PHA (1 gg/ml), whole digest of
OspA by cathepsin D (concentration unknown), and various fractions (Fx) of
the digest (concentrations unknown).

Figure 14

Proliferative responses of human nylon wool-purifed (NWP) T cells to
various stimuli, measured as 3Fl-thymidine incorporation and quantified as
counts per minute (cpm).

T cells from patient A.C. were incubated for two

days with the indicated antigens in the company of APCs, then pulsed with
3Ff-thymidine for four hours.

Stimuli included assay medium alone

(supplemented with autologous serum), rOspA (50 pg/ml), whole digest of
OspA by cathepsin D (concentration unknown), and various fractions (Fx) of
the digest (concentrations unknown).
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hybridomas with recombinant OspA (non-irradiated APCs)
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Interleukin Quantification Assay: Screening of T cell
hybridomas with recombinant OspA (newly prepared medium and antigen)

"d

n

H-4

o
o
o
o
Ol
o
o
o

H-1

n

tn
o
o
o

t—4
o
o
o
o

cn
o
o
o

ro
o
o
o
o

re
Hf
rt>

ro
en
o
o
o

I—i

tr ^

^ O
* 3
p
a 3
o
p

c«

n
P

<-i>
h-*
3

>
re <z»
V)
n p
l-t

3
p
3

CD
n
H
re
3

O

3
<2 ciq
>

Ss

3

re
S
H
o
re

Figure 7

o

C

n

3

ho

ro

l=4«

3*
h
a>
n
O
3
cr
i—• •
3
w

3

O
</>
TS

»>
l-t

>

CfQ

Source of supernatant

r-r»

3
a>
3

CD

Interleukin Quantification Assay: Stimulation of hybridoma #12
$

3

00
o
o
o
o
Ol
o
o
o
o
4^
O
o
o
o
CO
o
o
o
o
H-1

N>
o
o
o
o
o
o
o
o

Stimulation of human NWP T cells by cathepsin D-digested OspA
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